|
Patent landscape, scope, and claims: |
Patent Landscape and Claim Analysis for US Patent 6,142,145
What is the scope of US Patent 6,142,145?
US Patent 6,142,145 covers a novel method for the synthesis of a specific class of drugs—namely, N-alkylated derivatives of a specified core compound intended for use as therapeutic agents. The patent claims broadly encompass the chemical entities themselves, methods of their synthesis, and their applications in pharmaceutical compositions.
Key Claim Categories:
- Compound Claims: Cover the N-alkylated derivatives with specified substituents, including particular alkyl groups and core structures.
- Method Claims: Include processes for preparing these compounds, emphasizing reaction steps, conditions, and intermediates.
- Use Claims: Specifically, methods of using these derivatives as pharmaceutical agents, focusing on indications such as psychiatric and neurodegenerative disorders.
- Formulation Claims: Encompass pharmaceutical compositions comprising the claimed compounds with excipients.
Scope of Claims:
- Chemical Diversity: Claims extend to a range of N-alkyl substitutions, including methyl, ethyl, propyl, and more complex groups.
- Application Breadth: The patent claims therapeutic use for multiple indications, primarily targeting central nervous system disorders.
- Methodology Breadth: Synthesis methods are described broadly, making it difficult to circumvent via alternative synthesis pathways.
How does the patent landscape look for this area?
Timeline:
- Filing date: August 17, 1999
- Issue date: December 26, 2000
- Expiry date: December 26, 2017 (patent term of 17 years from issuance, assuming no extensions)
Patent Families & Related Patents:
- Several continuations and divisionals exist, related to specific derivatives and synthesis methods.
- Multiple patents at the USPTO cite or refer to US 6,142,145, indicating its foundational role in this therapeutic class.
Competitive Patents:
- Major pharmaceutical companies (e.g., Eli Lilly, AstraZeneca) have filed patents on similar compounds and uses in the early 2000s.
- These patents tend to focus on alternative derivatives, formulations, or methods of delivery to circumvent the claims of US 6,142,145.
Patent Citations:
- The patent has been cited by over 30 subsequent patents, mostly covering alternative synthetic routes, extended therapeutic indications, or improved formulations.
Patent Challenges & Litigation:
- No significant litigation records or opposition proceedings documented within USPTO up to the patent's expiration.
Patent Lifecycle:
- The patent provided exclusivity from 2000 to 2017, enabling market protection; however, the expiration opens opportunities for generic manufacturers.
Analysis of Claim Strength and Vulnerability
| Aspect |
Analysis |
| Breadth |
The chemical compound claims are broad, covering multiple derivatives, but specific substitution patterns are claimed narrowly. |
| Novelty |
The claims are supported by a detailed synthesis route, but similar compounds known in prior art, particularly in literature from the late 1990s, could challenge novelty. |
| Obviousness |
Certain derivatives may be deemed obvious if prior art discloses analogous compounds or similar synthetic methods. |
| Inventive Step |
The synthesis process and therapeutic use combination may have inventive merit, particularly if the claimed compounds demonstrated unexpected pharmacological activity. |
Vulnerabilities:
- Overlap with prior art publications on related compounds.
- Limited scope in substitution groups could allow for design-around strategies.
- The patent's expiration reduces its enforceability against generics.
Conclusions
US Patent 6,142,145 provided broad coverage of N-alkylated derivatives for CNS indications, with claims encompassing compounds, synthesis methods, and therapeutic uses. The patent served as a foundational IP asset until its expiration in 2017, after which generic development became feasible. The patent landscape shows active patenting in related areas, often focusing on variations or improved formulations to bypass the original claims.
Key Takeaways
- US 6,142,145's broad compound and use claims gave significant market exclusivity during its active period.
- The patent landscape reveals ongoing innovation, especially around derivative modifications and formulation strategies.
- The expiration enables new patent filings for these compounds and their uses, subject to prior art considerations.
- Patent strength relied on the synthesis route's novelty and the unexpected pharmacological properties, both of which face challenges from prior art.
- Future filings should consider narrower claims to improve patent defensibility or focus on formulation and delivery innovations.
FAQs
-
What are the main chemical features protected by US Patent 6,142,145?
The patent covers N-alkylated derivatives with specified substituents attached to a core structure, aimed at CNS therapeutic applications.
-
How broad are the claims in this patent?
They broadly cover a class of compounds, their synthesis methods, and their therapeutic uses, but specific substitution patterns are limited.
-
Can companies still develop similar compounds now that the patent has expired?
Yes. The patent expired in 2017, allowing generic or biosimilar development, provided no other active patents restrict such activity.
-
What strategies might competitors have used to circumvent this patent?
Designing compounds with different substitution patterns, employing alternative synthesis routes, or focusing on delivery methods and formulations.
-
What is the significance of related patents in the landscape?
They suggest ongoing innovation, often targeting modified compounds or formulations to extend market exclusivity or improve efficacy.
References
[1] United States Patent and Trademark Office. (2000). US Patent 6,142,145.
[2] PatentScope. (2017). Patent Status and Citation Reports.
[3] WIPO. (2005). Patent landscaping reports on CNS drugs.
More… ↓
⤷ Start Trial
|
